Anderson v. Bayer Corp.

610 F.3d 390, 2010 U.S. App. LEXIS 12769, 2010 WL 2485934
CourtCourt of Appeals for the Seventh Circuit
DecidedJune 22, 2010
Docket10-8003, 10-8004, 10-8005, 10-8006
StatusPublished
Cited by27 cases

This text of 610 F.3d 390 (Anderson v. Bayer Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Anderson v. Bayer Corp., 610 F.3d 390, 2010 U.S. App. LEXIS 12769, 2010 WL 2485934 (7th Cir. 2010).

Opinion

*392 FLAUM, Circuit Judge.

Defendants (collectively referred to as “Bayer”) have petitioned for leave to appeal the remand orders issued by the district court in the four above-captioned cases. In five separate, mostly identical complaints in state court, plaintiffs sued Bayer for personal injuries they allege were caused by Trasylol, a prescription medication manufactured by Bayer. Defendants removed, invoking the “mass action” provision of the Class Action Fairness Act (“CAFA”), which allows the removal of cases joining the claims of at least 100 plaintiffs that otherwise meet CAFA’s jurisdictional requirements. The district court remanded four of the five cases because they contained fewer than 100 plaintiffs (in the fifth case plaintiffs meant to include 99 plaintiffs, but actually named two-coexecutors in the same paragraph for a total of 100 plaintiffs). Bayer asks us to grant its petitions for review in the four cases remanded to state court and hold that (1) plaintiffs cannot avoid federal diversity jurisdiction by carving their filings into five separate pleadings, and (2) there is diversity jurisdiction over most plaintiffs claims because the claims of the small number of non-diverse plaintiffs were fraudulently misjoined and should be severed. Because we agree with the district court on the first question, we conclude that we are without jurisdiction to reach the second.

In August and September of 2009, plaintiffs’ counsel filed in St. Clair County, Illinois, claims on behalf of 57 unrelated plaintiffs, dividing the claims between four virtually identical complaints, using verbatim language, alleging that the plaintiffs (or their decedents) suffered injuries as a result of being administered Trasylol during heart surgery. Bayer removed, invoking the district court’s diversity jurisdiction over the diverse plaintiffs’ claims by arguing that the few non-diverse plaintiffs had been fraudulently misjoined. The district court remanded sua sponte.

After remand to St. Clair County, plaintiffs’ counsel amended the complaints to add 111 new plaintiffs, spread across the four existing suits. This resulted in a total of 100 plaintiffs in Gilmore, 1 5 in Brown, 45 in Bancroft, and 18 in Lecker. Plaintiffs’ counsel also filed a fifth complaint, Anderson, naming three plaintiffs, one of whom was non-diverse. Defendants once again removed. The district court remanded Bancroft, Brown, Lecker, and Anderson, rejecting defendants’ argument that they should be treated as a single mass action and defendants’ alternative argument that the non-diverse plaintiffs should have been severed from the action as fraudulently misjoined. Defendants then filed this petition for permission to appeal under 28 U.S.C. § 1453(c), a provision of CAFA that creates an exception for class actions to the general rule that remand orders are not reviewable. See id.; 28 U.S.C. § 1447(d).

Bayer first argues that plaintiffs’ cases meet CAFA’s definition of a “mass action” and thus the district court erred in remanding the cases. 28 U.S.C. § 1332(d)(ll)(B)(i) defines a mass action as “any civil action ... in which the monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that the plaintiffs’ claims involve common questions of law or fact.” Under CAFA, such mass actions “shall be deemed to be a class action” removable to federal court, so *393 long as CAFA’s other jurisdictional requirements are met. Id. § 1332(d)(ll)(A). There is no dispute that the other requirements — amount in controversy and minimal diversity' — 'are met in each of the four cases that Bayer appealed.

Of course, none of the instant four cases actually involve the claims of more than 100 plaintiffs. Bayer, however, urges us not to place “too much weight on form” in the CAFA context. See Marshall v. H & R Block Tax Servs., Inc., 564 F.3d 826, 828 (7th Cir.2009). They argue that plaintiffs’ five separate pleadings are a transparent attempt to circumvent CAFA, and, as such, should be treated as a single mass action. In support of this argument, they cite Freeman v. Blue Ridge Paper Products, Inc., 551 F.3d 405 (6th Cir.2008). In Freeman, the Sixth Circuit considered an appeal from the remand of five related cases that had separated the plaintiffs’ claims for nuisance into six-month periods in order to avoid meeting CAFA’s $5 million jurisdictional amount. Id. at 407. The Sixth Circuit found that “there was no colorable reason for breaking up the lawsuit in this fashion, other than to avoid federal jurisdiction,” and thus held that the damages sought in each suit “must be aggregated” for the purpose of determining whether the amount-in-controversy requirement had been met. Id.

Freeman, however, did not address the mass action provision of CAFA. This distinction is important because CAFA states that “the term ‘mass action’ shall not include any civil action in which the claims are joined upon motion of a defendant.” 28 U.S.C. § 1332(d)(ll)(B)(ii)(II). By excluding cases in which the claims were consolidated on a defendant’s motion, Congress appears to have contemplated that some cases which could have been brought as a mass action would, because of the way in which the plaintiffs chose to structure their claims, remain outside of CAFA’s grant of jurisdiction. This is not necessarily anomalous; after all, the general rule in a diversity case is that “plaintiffs as masters of the complaint may include (or omit) claims or parties in order to determine the forum.” See Garbie v. DaimlerChrysler Corp., 211 F.3d 407, 410 (7th Cir.2000) (citing Caterpillar Inc. v. Williams, 482 U.S. 386, 392, 107 S.Ct. 2425, 96 L.Ed.2d 318 (1987)).

The only appellate court to have addressed an argument similar to Bayer’s has rejected its approach. In Tanoh v. Dow Chemical Co., 561 F.3d 945 (9th Cir. 2009), the Ninth Circuit considered whether seven similar cases, each involving fewer than 100 plaintiffs, could be treated as a single mass action for CAFA purposes. The Tanoh court began by noting that under the plain language of CAFA, none of the state court cases were a mass action because they contained fewer than 100 plaintiffs each. Id. at 953.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Eagle U.S. 2, L.L.C. v. Abraham
627 F. App'x 351 (Fifth Circuit, 2015)
Justine Briggs v. Merck Sharp & Dohme
796 F.3d 1038 (Ninth Circuit, 2015)
Margalit Corber v. Xanodyne Pharmaceuticals, Inc.
771 F.3d 1218 (Ninth Circuit, 2014)
Time Insurance v. Astrazeneca AB
52 F. Supp. 3d 705 (E.D. Pennsylvania, 2014)
Teague v. Johnson & Johnson
749 F.3d 879 (Tenth Circuit, 2014)
Dawn Atwell v. Boston Scientific Corporation
740 F.3d 1160 (Eighth Circuit, 2013)
Halliburton v. Johnson & Johnson
983 F. Supp. 2d 1355 (W.D. Oklahoma, 2013)
Judith Romo v. Teva Pharmaceuticals USA, Inc.
731 F.3d 918 (Ninth Circuit, 2013)
Jarl Abrahamsen v. ConocoPhillips
503 F. App'x 157 (Third Circuit, 2012)
Abbott Laboratories v. Rhealyn Alexander
698 F.3d 568 (Seventh Circuit, 2012)
Mississippi ex rel. Hood v. AU Optronics Corp.
876 F. Supp. 2d 758 (S.D. Mississippi, 2012)
Nevada v. Bank of America Corp.
672 F.3d 661 (Ninth Circuit, 2012)
Lg Display Company v. Lisa Madigan
665 F.3d 768 (Seventh Circuit, 2011)
Illinois v. AU OPTRONICS CORP.
794 F. Supp. 2d 845 (N.D. Illinois, 2011)
Koral v. Boeing Co.
628 F.3d 945 (Seventh Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
610 F.3d 390, 2010 U.S. App. LEXIS 12769, 2010 WL 2485934, Counsel Stack Legal Research, https://law.counselstack.com/opinion/anderson-v-bayer-corp-ca7-2010.